Home ASCO 2026: Direct Kill + Immune Activation — CELMoD Drug Mezigdomide Shows Promise in Breaking Through Multiple Drug-Resistant, High-Risk Myeloma

ASCO 2026: Direct Kill + Immune Activation — CELMoD Drug Mezigdomide Shows Promise in Breaking Through Multiple Drug-Resistant, High-Risk Myeloma

May 29, 2026 20:41 CST Updated 22:03